Neuraminidase Inhibitors for Critically Ill Children With Influenza

OBJECTIVE: Timely treatment with neuraminidase inhibitor (NAI) drugs appears to improve survival in adults hospitalized with influenza. We analyzed California surveillance data to determine whether NAI treatment improves survival in critically ill children with influenza. METHODS: We analyzed data abstracted from medical records to characterize the outcomes of patients aged 0 to 17 years hospitalized in ICUs with laboratory-confirmed influenza from April 3, 2009, through September 30, 2012. RESULTS: Seven hundred eighty-four influenza cases aged <18 years hospitalized in ICUs had information on treatment. Ninety percent (532 of 591) of cases during the 2009 H1N1 pandemic (April 3, 2009–August 31, 2010) received NAI treatment compared with 63% (121 of 193) of cases in the postpandemic period (September 1, 2010–September 30, 2012; P < .0001). Of 653 cases NAI-treated, 38 (6%) died compared with 11 (8%) of 131 untreated cases (odds ratio = 0.67, 95% confidence interval: 0.34–1.36). In a multivariate model that included receipt of mechanical ventilation and other factors associated with disease severity, the estimated risk of death was reduced in NAI-treated cases (odds ratio 0.36, 95% confidence interval: 0.16–0.83). Treatment within 48 hours of illness onset was significantly associated with survival (P = .04). Cases with NAI treatment initiated earlier in illness were less likely to die. CONCLUSIONS: Prompt treatment with NAIs may improve survival of children critically ill with influenza. Recent decreased frequency of NAI treatment of influenza may be placing untreated critically ill children at an increased risk of death.

[1]  D. Nunan,et al.  Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children-a review of unpublished data Protocol information , 2010 .

[2]  M. D. de José,et al.  Oseltamivir Treatment for Influenza in Hospitalized Children Without Underlying Diseases , 2013, The Pediatric infectious disease journal.

[3]  Jo Leonardi-Bee,et al.  Impact of Neuraminidase Inhibitor Treatment on Outcomes of Public Health Importance During the 2009–2010 Influenza A(H1N1) Pandemic: A Systematic Review and Meta-Analysis in Hospitalized Patients , 2012, The Journal of infectious diseases.

[4]  Carl O. Eriksson,et al.  Risk factors for mechanical ventilation in U.S. children hospitalized with seasonal influenza and 2009 pandemic influenza A* , 2012, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[5]  Robert Schechter,et al.  Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  W. Schaffner,et al.  Reduced influenza antiviral treatment among children and adults hospitalized with laboratory-confirmed influenza infection in the year after the 2009 pandemic. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  N. Dreyer,et al.  H5N1 avian influenza in children. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. Finelli,et al.  Antiviral Treatment of Influenza in Children , 2012, The Pediatric infectious disease journal.

[9]  C. Del Mar,et al.  Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children , 2014, Sao Paulo medical journal = Revista paulista de medicina.

[10]  Aseem Kumar,et al.  Timing of Oseltamivir Administration and Outcomes in Hospitalized Adults With Pandemic 2009 Influenza A(H1N1) Virus Infection , 2012 .

[11]  N. Dreyer,et al.  H 5 N 1 Avian In fl uenza in Children , 2012 .

[12]  R. Keren,et al.  Oseltamivir Shortens Hospital Stays of Critically Ill Children Hospitalized With Seasonal Influenza: A Retrospective Cohort Study , 2011, The Pediatric infectious disease journal.

[13]  J. Pachón,et al.  Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. , 2011, Chest.

[14]  Zijian Feng,et al.  Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. R. Pérez Padilla,et al.  Reducing Occurrence and Severity of Pneumonia Due to Pandemic H1N1 2009 by Early Oseltamivir Administration: A Retrospective Study in Mexico , 2011, PloS one.

[16]  C. Launes,et al.  2009 Influenza A H1N1 Infections: Delays in Starting Treatment With Oseltamivir Were Associated With a More Severe Disease , 2011, The Pediatric infectious disease journal.

[17]  J. Rello,et al.  Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. , 2011, The Journal of antimicrobial chemotherapy.

[18]  L. Gubareva,et al.  Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2011, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[19]  Stuart Berman,et al.  Sexually transmitted diseases treatment guidelines, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[20]  C. Jean,et al.  Children hospitalized with 2009 novel influenza A(H1N1) in California. , 2010, Archives of pediatrics & adolescent medicine.

[21]  N. Dreyer,et al.  Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. , 2010, The Journal of infectious diseases.

[22]  J. Sung,et al.  Outcomes of adults hospitalised with severe influenza , 2010, Thorax.

[23]  Michael Shaw,et al.  Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. , 2010, The New England journal of medicine.

[24]  A. Esteban,et al.  Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina , 2010, Intensive Care Medicine.

[25]  Lyn Finelli,et al.  Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. , 2009, The New England journal of medicine.

[26]  Robert Schechter,et al.  Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. , 2009, JAMA.

[27]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[28]  K. Ungchusak,et al.  Severe Human Influenza Infections in Thailand: Oseltamivir Treatment and Risk Factors for Fatal Outcome , 2009, PloS one.

[29]  M. Glynn,et al.  Recommendations and Reports , 2009 .

[30]  Robert Schechter,et al.  Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[31]  J. Farrar,et al.  Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series , 2008, The Lancet.

[32]  J. Raboud,et al.  Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[34]  P. Ward,et al.  Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. , 2003, Archives of internal medicine.

[35]  John J. Treanor,et al.  Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .

[36]  R. Harpaz,et al.  Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1996, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[37]  W. Roper,et al.  Prevention and control of influenza: Part I, Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1994, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.